Nature:中科院研究,有望抑制肺癌转移!

2019-06-27 医界小编 医界

在由中科院上海生化细胞所杨巍维博士与中国科学院大连化学物理研究所李国辉博士研究组合作发表于《Nature》的一篇研究中,研究者们进一步探索了癌症转移的机制,并为预防肿瘤转移提供一些新的思路。

肺癌是全世界最常见也最恐怖的癌症之一,尤其在中国。据今年1月国家癌症中心发布的2019年中国癌症报告,2015年(统计报告登记数据滞后3年)我国发病人数最多的癌症就是肺癌,超过五分之一的癌症患者都是肺癌的“受害者“,几乎两倍于第二名的癌。同样,在癌症致死人数中,肺癌也是牢牢占据第一名。根据柳叶刀2018年发布的数据,肺癌的五年生存率还不到20%。

癌症之所以如此致命,有一个关键原因就是癌症的转移性,据统计,癌症转移导致95%的癌症死亡,往往好不容易治疗好了一个部位,癌细胞却又鬼鬼祟祟跑到了另一个部位,治疗又得重新开始,倘若发现不及时,往往会酿成悲剧。

而今日,在由中科院上海生化细胞所杨巍维博士与中国科学院大连化学物理研究所李国辉博士研究组合作发表于《Nature》的一篇研究中,研究者们进一步探索了癌症转移的机制,并为预防肿瘤转移提供一些新的思路。

通常来说,原发性恶性肿瘤可以通过手术、放疗以及化疗等传统疗法进行较为有效的治疗,然而,通常也就止步于此了,这些传统疗法对转移性肿瘤的作用有限。

因此,了解肿瘤转移的分子机制有助于为早期发现肿瘤转移提供生物标志物,并且帮助研究者开发干预转移的新策略,从而为患者提供更好的预后。

癌细胞的一个标志性特征就是不正常的代谢,其会为自身重新编程代谢以支持它自身的生长及增殖,研究者们就是要探究这种代谢失调与肿瘤转移之间的联系。

UDP-葡萄糖脱氢酶(UGDH)是糖醛酸途径中的限速酶,它催化UDP-葡萄糖生成UDP-葡萄糖醛酸并参与糖胺聚糖的生物合成。

研究者发现,在表皮生长因子受体(EGFR)激活后,UGDH在酪氨酸(tyrosine)473处被磷酸化。磷酸化的UGDH与HuR结合并将UDP-葡萄糖转化为UDP-葡糖醛酸,它减弱了UDP-葡萄糖介导的HuR与SNAI1 mRNA结合的抑制,因此反过来增强了SNAI1 mRNA的稳定性。

SNAI1可以编码产生Snail蛋白,这一蛋白会引发上皮与间质的转化,从而促进肿瘤细胞的迁移和肺癌转移,可通常情况下SNAI1 mRNA会被细胞中的一种酶降解,在被UGDH“强化”后,其稳定性得到了提高,可以“生产”足够多的Snail蛋白,也就达到了促进癌症转移的效果。

结合临床数据分析后,研究者们发现较低的UDP-葡萄糖水平与肺癌的转移和复发密切相关。他们观察到转移性肿瘤中的UDP-葡萄糖水平远低于原发性肿瘤。远端转移患者的UDP-葡萄糖水平远低于无远端转移的患者,肿瘤组织中UGDH Y473磷酸化水平高的患者转移率较高,预后较差。

研究者们此次的发现为肺癌转移的诊断提供了首个生物标志物,通过对于这一标志物的观察,将可以更早发现肿瘤的转移。

这一成果也许可以为预防肿瘤转移或癌症患者的预后治疗提供一些新的思路,对于其他研究者而言,也提供了一个看待肿瘤代谢标志物的新视角。

原始出处:
Xiongjun Wang, Ruilong Liu, et al. UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. Jun 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862666, encodeId=fa5c1862666ea, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Aug 30 22:56:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883746, encodeId=c1fe1883e469c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 07 23:56:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368678, encodeId=5afe3686e85a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jun 30 18:38:45 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590334, encodeId=0184159033454, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Jun 29 10:56:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368492, encodeId=c42e36849205, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Jun 28 06:42:08 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
    2019-08-30 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862666, encodeId=fa5c1862666ea, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Aug 30 22:56:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883746, encodeId=c1fe1883e469c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 07 23:56:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368678, encodeId=5afe3686e85a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jun 30 18:38:45 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590334, encodeId=0184159033454, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Jun 29 10:56:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368492, encodeId=c42e36849205, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Jun 28 06:42:08 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
    2019-10-07 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862666, encodeId=fa5c1862666ea, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Aug 30 22:56:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883746, encodeId=c1fe1883e469c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 07 23:56:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368678, encodeId=5afe3686e85a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jun 30 18:38:45 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590334, encodeId=0184159033454, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Jun 29 10:56:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368492, encodeId=c42e36849205, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Jun 28 06:42:08 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
    2019-06-30 一个字-牛

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1862666, encodeId=fa5c1862666ea, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Aug 30 22:56:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883746, encodeId=c1fe1883e469c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 07 23:56:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368678, encodeId=5afe3686e85a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jun 30 18:38:45 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590334, encodeId=0184159033454, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Jun 29 10:56:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368492, encodeId=c42e36849205, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Jun 28 06:42:08 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
    2019-06-29 linagood
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862666, encodeId=fa5c1862666ea, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Aug 30 22:56:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883746, encodeId=c1fe1883e469c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 07 23:56:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368678, encodeId=5afe3686e85a, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sun Jun 30 18:38:45 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590334, encodeId=0184159033454, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat Jun 29 10:56:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368492, encodeId=c42e36849205, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Jun 28 06:42:08 CST 2019, time=2019-06-28, status=1, ipAttribution=)]
    2019-06-28 thm112988

    0

相关资讯

JACC:肺癌患者心脏辐射剂量与不良预后相关

局部非小细胞肺癌(NSCLC)患者的放射治疗相关心脏毒性的研究受到样本量小和心脏终点无效的限制。本研究的目的旨在确定心脏辐射剂量是否为主要不良心血管事件(MACE)和全因死亡的预测因子。本研究纳入分析了748名接受胸部放疗的局部NSCLC患者,经过平均20.4个月时间的随访,77名患者出现有≥1个MACE(2年的累积发生率为5.8%,95% [CI]: 4.3%-7.7%),533名患者死亡。心脏

热议NGS检测在肺癌中的作用和驱动基因阳性NSCLC的治疗

第三届肺癌紫金论坛暨第二届江苏省肺癌综合诊疗新进展学习班和肺癌规范化诊疗培训班在南京市金陵饭店盛大召开。本次论坛由中国抗癌协会肿瘤临床化疗专业委员会、江苏省抗癌协会化疗专业委员会、江苏省肿瘤科医疗质量控制中心主办,邀请到国际、国内肿瘤领域知名专家齐聚金陵,聚焦肺癌诊疗最新进展,共襄难治性恶性肺癌诊治经验。就NGS(二代测序)检测在肺癌中的作用及驱动基因阳性晚期NSCLC的治疗选择进行探讨。

CA-CANCER J CLIN: 多种癌症的筛查指南

乳腺癌:40-54岁,1次/年,钼靶X线检查;55岁及以上,预期寿命长于10年,每年筛查2次。宫颈癌:21-29岁,1次/3年,常规的或巴式细胞法;30-65岁,1次/3年,巴式细胞法,或1次/5年,HPV检测+巴式细胞法;65岁以上,若在过去10年内连续3次巴式细胞法检测阴性或连续2次巴式细胞法+HPV检测阴性,则可终止宫颈癌筛查。PS. 宫颈癌疫苗注射与否,不影响筛查方案。子宫内膜癌:更年期的

开启局部晚期肺癌治疗“新模式”——听吴一龙教授解读CTONG1103研究发现

由广东省人民医院吴一龙教授和钟文昭教授牵头进行的全国多中心随机对照II期临床研究EMERGING(CTONG1103),旨在对比厄洛替尼和传统含铂双药作为IIIA N2期非小细胞肺癌(NSCLC)新辅助治疗的疗效及安全性。研究结果首次在2018年ESMO大会发布,2019年6月13日在JCO杂志正式发布。

陆舜教授:促进亚太地区肺癌诊疗水平的提高,中国专家任重而道远

浴兰时节,菖蒲酒美,契阔谈宴恰逢时。践行“一带一路”倡议,借助区域合作平台,积极拓展中国与亚太国家和地区的科学交流与合作,不遗余力推动“中国健康创新模式”,2019年6月13—14日,阿斯利康泛亚肺癌高峰论坛(Pan-Asia Lung Cancer Summit)隆重召开。会议邀请到韩国延世大学医学院的Byoung Chul Cho教授、美国Levine癌症研究所的Edward S.Kim教授,

抗肿瘤药物处方审核专家共识—肺癌

为了进一步规范肿瘤的药物治疗,促进临床合理用药,改善肺癌患者的预后,由国家癌症中心、国家肿瘤质控中心药事质控专家委员会牵头,中国抗癌协会肿瘤临床药学专业委员会、中国药师协会肿瘤药师分会共同组织全国药学专家,根据《医疗机构处方审核规范》及抗肿瘤药物管理相关规定,结合目前国内肿瘤专科药师临床处方审核的实践经验,制定了《肺癌抗肿瘤药物处方审核专家共识》。 本共识首次提出运用“六步法”进行抗肿瘤药物处方审